Last reviewed · How we verify
Motivation-Phase Nicotine Mini-Lozenge
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid for individuals motivated to quit smoking.
At a glance
| Generic name | Motivation-Phase Nicotine Mini-Lozenge |
|---|---|
| Also known as | Nicorette |
| Sponsor | VA Office of Research and Development |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine is a nicotinic acetylcholine receptor agonist that stimulates dopamine release in reward pathways, partially satisfying the brain's dependence on nicotine from cigarettes. By providing controlled nicotine delivery via a lozenge formulation, it reduces the severity of withdrawal symptoms and cravings, facilitating the transition away from smoking. The 'Motivation-Phase' designation suggests this product is intended for use during the active motivation and early cessation phase of smoking cessation therapy.
Approved indications
- Smoking cessation aid for nicotine dependence
Common side effects
- Mouth irritation
- Hiccups
- Nausea
- Headache
- Insomnia
Key clinical trials
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: